Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

[Prova del dispositivo che non è approvato o cancellato dalla FDA degli Stati Uniti] (APPRECIATE)

9 ottobre 2026 aggiornato da: AstraZeneca

The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a Phase 2b study to assess efficacy and safety of AZD2373 involving 3 study treatment arms in Part A and 2 study treatment arms in Part B where participants and study personnel including study investigators are blinded to the assigned treatment.

Participants with 300 mg/g or greater UACR and eGFR ≥ 25mL/min/1.73m2 will be recruited into the study. Participants on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant will be excluded.

The study will have Part A and Part B. Part A (n = 96) will have a 1:1:1 randomization of participants to subgroups receiving weekly subcutaneous injections of 50 mg AZD2373, 150 mg AZD2373, and placebo. Part B (n = 40) will have a 4:1 randomization of participants to subgroups receiving every other week subcutaneous injections of 150 mg or placebo. Part B will begin after Part A is completely enrolled.

Both Part A and Part B will have same participant criteria and schedules. The SoA and visit schedule will not change for Part B.

All participants will remain in the study on treatment until the last participant has completed 30 weeks of treatment. The treatment duration will be up to minimum of 30 weeks of study treatment.

All participants will have the opportunity to enter the OLE study.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

63

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Birmingham, Regno Unito, B15 2WB
        • Research Site
      • Leicester, Regno Unito, Le5 4PW
        • Research Site
      • Liverpool, Regno Unito, L22 0LG
        • Research Site
      • London, Regno Unito, SE1 9RT
        • Research Site
      • London, Regno Unito, NW3 2QG
        • Research Site
      • London, Regno Unito, SW17 0QT
        • Research Site
      • London, Regno Unito, SE5 8AZ
        • Research Site
      • London, Regno Unito, SM5 1AA
        • Research Site
      • London, Regno Unito, SW7 2AZ
        • Research Site
      • Manchester, Regno Unito, M13 9WL
        • Research Site
    • Alabama
      • Alabaster, Alabama, Stati Uniti, 35007
        • Research Site
      • Birmingham, Alabama, Stati Uniti, 35205
        • Research Site
      • Irondale, Alabama, Stati Uniti, 35210
        • Research Site
    • Arizona
      • Surprise, Arizona, Stati Uniti, 85374
        • Research Site
    • California
      • Beverly Hills, California, Stati Uniti, 90211
        • Research Site
      • Concord, California, Stati Uniti, 94520
        • Research Site
      • Fremont, California, Stati Uniti, 94538
        • Research Site
      • Gardena, California, Stati Uniti, 90247
        • Research Site
      • Los Angeles, California, Stati Uniti, 90095
        • Research Site
      • Valencia, California, Stati Uniti, 91355
        • Research Site
    • Florida
      • Boca Raton, Florida, Stati Uniti, 33487
        • Research Site
      • Brandon, Florida, Stati Uniti, 33511
        • Research Site
      • Miami, Florida, Stati Uniti, 33126
        • Research Site
      • Miami, Florida, Stati Uniti, 33173
        • Research Site
      • Orlando, Florida, Stati Uniti, 32808
        • Research Site
      • Pompano Beach, Florida, Stati Uniti, 33060
        • Research Site
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Research Site
      • Augusta, Georgia, Stati Uniti, 30912
        • Research Site
      • Augusta, Georgia, Stati Uniti, 30909
        • Research Site
      • Augusta, Georgia, Stati Uniti, 30904
        • Research Site
      • Columbus, Georgia, Stati Uniti, 31904
        • Research Site
      • Columbus, Georgia, Stati Uniti, 31901
        • Research Site
      • Duluth, Georgia, Stati Uniti, 30096
        • Research Site
      • Hinesville, Georgia, Stati Uniti, 31313
        • Research Site
      • Lawrenceville, Georgia, Stati Uniti, 30046
        • Research Site
      • Macon, Georgia, Stati Uniti, 31217
        • Research Site
      • Macon, Georgia, Stati Uniti, 31210
        • Research Site
      • Marietta, Georgia, Stati Uniti, 30067
        • Research Site
      • Savannah, Georgia, Stati Uniti, 31406
        • Research Site
      • Stockbridge, Georgia, Stati Uniti, 30281
        • Research Site
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
        • Research Site
      • Chicago, Illinois, Stati Uniti, 60643
        • Research Site
      • Hinsdale, Illinois, Stati Uniti, 60521
        • Research Site
      • Rockford, Illinois, Stati Uniti, 61107
        • Research Site
    • Louisiana
      • Baton Rouge, Louisiana, Stati Uniti, 70808
        • Research Site
      • Lafayette, Louisiana, Stati Uniti, 70508
        • Research Site
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Research Site
      • Shreveport, Louisiana, Stati Uniti, 71103
        • Research Site
    • Maryland
      • Bethesda, Maryland, Stati Uniti, 20889
        • Research Site
      • Potomac, Maryland, Stati Uniti, 20854
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Research Site
      • Worcester, Massachusetts, Stati Uniti, 01608
        • Research Site
    • Michigan
      • Lansing, Michigan, Stati Uniti, 48911
        • Research Site
      • Roseville, Michigan, Stati Uniti, 48066
        • Research Site
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55455
        • Research Site
    • Mississippi
      • Columbus, Mississippi, Stati Uniti, 39705
        • Research Site
      • Tupelo, Mississippi, Stati Uniti, 38801
        • Research Site
    • New York
      • Brooklyn, New York, Stati Uniti, 11203
        • Research Site
      • Brooklyn, New York, Stati Uniti, 11221
        • Research Site
      • Laurelton, New York, Stati Uniti, 11413
        • Research Site
      • New York, New York, Stati Uniti, 10010
        • Research Site
      • Rockville Centre, New York, Stati Uniti, 11570
        • Research Site
      • The Bronx, New York, Stati Uniti, 10461
        • Research Site
    • North Carolina
      • Cary, North Carolina, Stati Uniti, 27511
        • Research Site
      • Durham, North Carolina, Stati Uniti, 27705
        • Research Site
      • Fayetteville, North Carolina, Stati Uniti, 28304
        • Research Site
      • Gastonia, North Carolina, Stati Uniti, 28054
        • Research Site
      • Greenville, North Carolina, Stati Uniti, 27834
        • Research Site
      • Jacksonville, North Carolina, Stati Uniti, 28546
        • Research Site
      • Kinston, North Carolina, Stati Uniti, 28501
        • Research Site
      • Winston-Salem, North Carolina, Stati Uniti, 27103
        • Research Site
      • Winston-Salem, North Carolina, Stati Uniti, 27157
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45246
        • Research Site
      • Columbus, Ohio, Stati Uniti, 43210
        • Research Site
    • Pennsylvania
      • Bridgeville, Pennsylvania, Stati Uniti, 15017
        • Research Site
      • Butler, Pennsylvania, Stati Uniti, 16001
        • Research Site
      • Exton, Pennsylvania, Stati Uniti, 19341
        • Research Site
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Research Site
    • South Carolina
      • Anderson, South Carolina, Stati Uniti, 29621
        • Research Site
      • Columbia, South Carolina, Stati Uniti, 29203
        • Research Site
      • Orangeburg, South Carolina, Stati Uniti, 29118
        • Research Site
      • Spartanburg, South Carolina, Stati Uniti, 29306
        • Research Site
    • Tennessee
      • Chattanooga, Tennessee, Stati Uniti, 37404
        • Research Site
      • Nashville, Tennessee, Stati Uniti, 37232
        • Research Site
    • Texas
      • Conroe, Texas, Stati Uniti, 77304
        • Research Site
      • Conroe, Texas, Stati Uniti, 77384
        • Research Site
      • Dallas, Texas, Stati Uniti, 75234
        • Research Site
      • Dallas, Texas, Stati Uniti, 75235
        • Research Site
      • Houston, Texas, Stati Uniti, 77054
        • Research Site
      • Katy, Texas, Stati Uniti, 77450
        • Research Site
      • Mesquite, Texas, Stati Uniti, 75149
        • Research Site
      • Pearland, Texas, Stati Uniti, 77584
        • Research Site
      • San Antonio, Texas, Stati Uniti, 78212
        • Research Site
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23510
        • Research Site
      • Portsmouth, Virginia, Stati Uniti, 23708
        • Research Site
      • Richmond, Virginia, Stati Uniti, 23298
        • Research Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age: Male and female participants of African descent (including, but not limited to, Black, Black African, Black Caribbean, African American, Afro-Caribbean, Afro-Latino, West African, Mixed Black backgrounds, or other self-identified African diaspora heritage) aged 18 to 70 years, inclusive at the time of informed consent.
  • Participants who have high-risk APOL1 genotype (G1/G1; G1/G2; G2/G2). The screening period can be extended if there are delays related to the shipment, handling, or processing of genotype results.
  • A geometric mean UACR ≥ 300 mg/g calculated based on the mean of readings taken from 3 FMV urine samples collected on 3 consecutive days. Since the mean will be assessed for eligibility, any of the 3 readings may fall below 300 mg/g.
  • eGFR ≥ 25 mL/min/1.73m2.
  • Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion Criteria:

  • Participants with diagnosis of Type 1 diabetes mellitus.

  • Body Mass Index > 45 kg/m2.

  • SBP > 180 mmHg/DBP > 110 mmHg (measured when the participant is considered to be at steady state, and preferably when they have taken their BP medications that same day).

  • QTcF > 470 ms, except participants with bundle branch block who should excluded if QTcF> 480 ms.

  • Acute coronary syndrome/Acute myocardial infraction with or without any coronary intervention within 6 months.

  • Transient ischaemic attack/ stroke within 3 months.

  • High grade (second to third) degree AV block or clinically significant sinus node dysfunction untreated with pacemaker.

  • A history of ventricular arrhythmias requiring treatment.

  • Participants with Type 2 diabetes mellitus must be excluded if ANY of the following conditions are present:

    1. Current or past use of insulin for more than 3 months and/or any maintenance therapy with insulin within 2 months of screening.
    2. Screening Haemoglobin A1c > 8.0%
    3. Receiving more than one anti-hyperglycaemic agent (excluding SGLT inhibitors and GLP-1 receptor agonists is permitted if prescribed for a purpose other than glycaemic control which can be taken in addition to one other anti-hyperglycaemic agent).
  • Participant on kidney replacement therapy (dialysis or kidney transplant) or any other organ transplant.

  • History or serologic evidence of autoimmune-mediated glomerular disease including but not limited to: lupus nephritis (positive lupus serology), ANCA associated vasculitis (antineutrophil cytoplasmic antibody), membranous nephropathy (anti-phospholipase A2 receptor antibody or other autoantibody associated with membranous nephropathy), anti-GBM disease (anti-GBM antibody), or IgA nephropathy.

  • Another underlying cause of kidney disease that is not associated with APOL1, including but not limited to polycystic kidney disease or, congenital anomalies of the kidney and urinary tract.

  • History of a diagnosed coagulopathy, a major unexplained bleeding event, or other high-risk bleeding diathesis.

  • A history of trypanosomiasis or leishmaniasis.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Part A - Placebo group

Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose.

Accessorized Pre-Filled Syringe (Solution for injection).

The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.

Sperimentale: Part A - AZD2373 - Arm 1

Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose.

The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.

Accessorized Pre-Filled Syringe (Solution for injection)

Sperimentale: Part A - AZD2373 - Arm 2

Participants will be randomized at a 1:1:1 ratio to 3 study treatment arms. Participants will receive SC injection of the assigned dose.

The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.

Accessorized Pre-Filled Syringe (Solution for injection)

Sperimentale: Part B - AZD2373 Arm 1

Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose

The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.

Accessorized Pre-Filled Syringe (Solution for injection)

Comparatore placebo: Part B - Placebo group

Participants will be randomized at a 4:1 ratio to 2 study treatment arms. Participants will receive SC injection of the assigned dose

Accessorized Pre-Filled Syringe (Solution for injection).

The APOL1 Genotyping Clinical Trial Assay, an investigational use only qualitative Polymerase Chain Reaction invitro diagnostic assay, discriminates between the rs73885319 G1(S342G) and rs71785313 G2 genotypes within the APOL1 gene from DNA extracted from whole blood.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Relative change in Urine Albumin-Creatinine Ratio (UACR)
Lasso di tempo: From Baseline at Week 30

To assess the effect of AZD2373 versus placebo in reducing albuminuria

From Baseline at Week 30

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Relative change in Urine Albumin-Creatinine Ratio (UACR)
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)

To assess the effect of AZD2373 versus placebo in reducing albuminuria

From Baseline at the End of Treatment (Until the last participant completes Week 30)
Relative change in Urine Protein-Creatinine Ratio (UPCR)
Lasso di tempo: From Baseline at Week 30

To assess the effect of AZD2373 versus placebo in reducing proteinuria

From Baseline at Week 30
Relative change in Urine Protein-Creatinine Ratio (UPCR)
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)

To assess the effect of AZD2373 versus placebo in reducing proteinuria

From Baseline at the End of Treatment (Until the last participant completes Week 30)
Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)
Lasso di tempo: From Baseline at Week 30

To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment

From Baseline at Week 30
Proportion of participants achieving a 45% or greater reduction in Urine Albumin-Creatinine Ratio (UACR)
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)

To assess the proportion of participants achieving a 45% or greater Urine Albumin-Creatinine Ratio (UACR) reduction by treatment

From Baseline at the End of Treatment (Until the last participant completes Week 30)
eGFR slope
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)

To assess pooled AZD2373 doses versus placebo on eGFR change

From Baseline at the End of Treatment (Until the last participant completes Week 30)
Incidence of development of ADA and ADA titer (if participants are ADA-positive)
Lasso di tempo: During treatment (up to Week 30) and follow-up (up to 12 weeks)

To evaluate the immunogenicity of AZD2373

During treatment (up to Week 30) and follow-up (up to 12 weeks)
Plasma concentration
Lasso di tempo: From Baseline at the End of Treatment (Until the last participant completes Week 30)

To evaluate the PK of AZD2373

From Baseline at the End of Treatment (Until the last participant completes Week 30)
Adverse Events (AEs), Serious Adverse Events (SAEs), and Drug Adverse Events (DAEs).
Lasso di tempo: From baseline at the End of Treatment (Until the last participant completes Week 30)

To assess the safety and tolerability of ranging doses of AZD2373. These events will be collected according to the timepoints specified in the schedule of assessments, starting from the time of signing the Informed Consent Form (ICF).

From baseline at the End of Treatment (Until the last participant completes Week 30)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 marzo 2025

Completamento primario (Stimato)

4 ottobre 2027

Completamento dello studio (Stimato)

4 ottobre 2027

Date di iscrizione allo studio

Primo inviato

24 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

7 febbraio 2025

Primo Inserito (Effettivo)

13 febbraio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • D6800C00005

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Periodo di condivisione IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criteri di accesso alla condivisione IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.

Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .